Literature DB >> 21789055

PET/CT imaging of clear cell renal cell carcinoma with I labeled chimeric antibody.

Eamonn E Bahnson1, Douglas A Murrey, Cathy M Mojzisik, Nathan C Hall, Humberto J Martinez-Suarez, Michael V Knopp, Edward W Martin, Stephen P Povoski, Robert R Bahnson.   

Abstract

Clear cell renal cell carcinoma (ccRCC) presents problems for urologists in diagnosis, treatment selection, intraoperative surgical margin analysis, and long term monitoring. In this paper we describe the development of a radiolabeled antibody specific to ccRCC (124I-cG250) and its potential to help urologists manage each of these problems. We believe 124I-cG250, in conjunction with perioperative Positron emission tomography/computed tomography imaging and intraoperative handheld gamma probe use, has the potential to diagnose ccRCC, aid in determining a proper course of treatment (operative or otherwise), confirm complete resection of malignant tissue in real time, and monitor patients post-operatively.

Entities:  

Keywords:  advanced kidney cancer; kidney cancer; kidney cancer basic research; kidney cancer evaluation/staging; kidney cancer localized

Year:  2009        PMID： 21789055      PMCID： PMC3126050          DOI： 10.1177/1756287209105264

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN： 1756-2872


  17 in total

1.  Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup.

Authors:  A F Fergany; K S Hafez; A C Novick
Journal:  J Urol       Date:  2000-02       Impact factor: 7.450

2.  Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney.

Authors:  E Oosterwijk; D J Ruiter; P J Hoedemaeker; E K Pauwels; U Jonas; J Zwartendijk; S O Warnaar
Journal:  Int J Cancer       Date:  1986-10-15       Impact factor: 7.396

3.  Open partial nephrectomy for tumor in a solitary kidney: experience with 400 cases.

Authors:  Amr F Fergany; Ismail R Saad; Lynn Woo; Andrew C Novick
Journal:  J Urol       Date:  2006-05       Impact factor: 7.450

4.  Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer.

Authors:  Hideshi Miyakita; Masatosi Tokunaga; Hajime Onda; Yukio Usui; Hidechika Kinoshita; Nobuo Kawamura; Seiei Yasuda
Journal:  Int J Urol       Date:  2002-01       Impact factor: 3.369

5.  Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma.

Authors:  David E Kang; Richard L White; James H Zuger; Howell C Sasser; Chris M Teigland
Journal:  J Urol       Date:  2004-05       Impact factor: 7.450

6.  Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.

Authors:  Chaitanya R Divgi; Neeta Pandit-Taskar; Achim A Jungbluth; Victor E Reuter; Mithat Gönen; Shutian Ruan; Christine Pierre; Andrew Nagel; Daniel A Pryma; John Humm; Steven M Larson; Lloyd J Old; Paul Russo
Journal:  Lancet Oncol       Date:  2007-04       Impact factor: 41.316

7.  F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.

Authors:  Navneet S Majhail; Jean-Luc Urbain; Justin M Albani; Mangesh H Kanvinde; Thomas W Rice; Andrew C Novick; Tarek M Mekhail; Thomas E Olencki; Paul Elson; Ronald M Bukowski
Journal:  J Clin Oncol       Date:  2003-11-01       Impact factor: 44.544

8.  Multimodality approach of perioperative 18F-FDG PET/CT imaging, intraoperative 18F-FDG handheld gamma probe detection, and intraoperative ultrasound for tumor localization and verification of resection of all sites of hypermetabolic activity in a case of occult recurrent metastatic melanoma.

Authors:  Stephen P Povoski; Nathan C Hall; Edward W Martin; Michael J Walker
Journal:  World J Surg Oncol       Date:  2008-01-10       Impact factor: 2.754

9.  Combined approach of perioperative 18F-FDG PET/CT imaging and intraoperative 18F-FDG handheld gamma probe detection for tumor localization and verification of complete tumor resection in breast cancer.

Authors:  Nathan C Hall; Stephen P Povoski; Douglas A Murrey; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2007-12-21       Impact factor: 2.754

10.  Combined use of preoperative 18F FDG-PET imaging and intraoperative gamma probe detection for accurate assessment of tumor recurrence in patients with colorectal cancer.

Authors:  Ismet Sarikaya; Stephen P Povoski; Osama H Al-Saif; Ergun Kocak; Mark Bloomston; Steven Marsh; Zongjian Cao; Douglas A Murrey; Jun Zhang; Nathan C Hall; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2007-07-16       Impact factor: 2.754
View more
  4 in total

1.  Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.

Authors:  Narges K Tafreshi; Mark C Lloyd; Joshua B Proemsey; Marilyn M Bui; Jongphil Kim; Robert J Gillies; David L Morse
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

2.  Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial.

Authors:  Chaitanya R Divgi; Robert G Uzzo; Constantine Gatsonis; Roman Bartz; Silke Treutner; Jian Qin Yu; David Chen; Jorge A Carrasquillo; Steven Larson; Paul Bevan; Paul Russo
Journal:  J Clin Oncol       Date:  2012-12-03       Impact factor: 44.544

3.  Multimodal imaging and detection strategy with 124 I-labeled chimeric monoclonal antibody cG250 for accurate localization and confirmation of extent of disease during laparoscopic and open surgical resection of clear cell renal cell carcinoma.

Authors:  Stephen P Povoski; Nathan C Hall; Douglas A Murrey; David S Sharp; Charles L Hitchcock; Cathy M Mojzisik; Eamonn E Bahnson; Michael V Knopp; Edward W Martin; Robert R Bahnson
Journal:  Surg Innov       Date:  2012-03-27       Impact factor: 2.058

Review 4.  Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124.

Authors:  Krishan Kumar; Arijit Ghosh
Journal:  Molecules       Date:  2021-01-14       Impact factor: 4.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.